Brought to you by 
Guilford Pharmaceuticals gets $27.2mm from investors
18 Dec 2003
Executive Summary
Guilford Pharmaceuticals (therapeutics for neurology and hospital markets) sold 4.8mm common shares at $5.67 each (a 15% discount to market), grossing $27.2mm, to Sage Capital, OrbiMed Advisors, Highbridge Capital, Domain Associates, UBS O'Connor LLC, Quogue Capital, and Merlin BioMed. The investors also received 7-year warrants to buy about 961.4k additional common shares at $7.55 each.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Guilford Pharmaceuticals gets $27.2mm from investors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice